A conjugated or labeled antibody is a polyclonal or monoclonal antibody with an attached reporter molecule that generates a signal through color, fluorescence, radioactivity, or enzymatic activity, ...
Antibody-drug conjugates (ADCs) are transforming targeted cancer therapy, with innovations in conjugation chemistry and payload-linker technologies driving improvements in efficacy, stability, and ...
Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the ...
Ajinomoto Co., Inc. has signed a licensing agreement with Astellas Pharma Inc. for the use of AJICAP—an antibody-drug conjugate (ADC) development and manufacturing technology—as part of its CDMO ...
An antibody-drug conjugate (ADC) is a newly developed, highly-targeted type of cancer therapeutic. ADCs are created by grafting monoclonal antibodies to a cytotoxic payload. This new type of cancer ...
VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics discovery, and Fina Biosolutions LLC (FinaBio), experts in ...
GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...
Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the ...
GSK acquires exclusive rights from Syndivia for antibody-drug conjugate in prostate cancer: London, UK Tuesday, October 28, 2025, 09:00 Hrs [IST] GSK plc and Syndivia, a private b ...
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the antibody-drug conjugate JSKN003 for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback